Compare INCR & GDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INCR | GDL |
|---|---|---|
| Founded | 1994 | 2006 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.3M | 94.9M |
| IPO Year | N/A | N/A |
| Metric | INCR | GDL |
|---|---|---|
| Price | $1.18 | $8.46 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 46.0K | 11.2K |
| Earning Date | 10-08-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.02% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $72,158,312.00 | N/A |
| Revenue This Year | $69.54 | N/A |
| Revenue Next Year | $41.75 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.22 | $7.65 |
| 52 Week High | $1.79 | $8.13 |
| Indicator | INCR | GDL |
|---|---|---|
| Relative Strength Index (RSI) | 37.69 | 47.56 |
| Support Level | $1.35 | $8.34 |
| Resistance Level | $1.51 | $8.53 |
| Average True Range (ATR) | 0.07 | 0.09 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 13.90 | 47.50 |
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.
GDL Fund is a diversified closed-end management investment company. Its primary investment objective is to achieve absolute returns in various market conditions without excessive risk of capital. The fund seeks to achieve its objective by investing in merger arbitrage transactions and, to a lesser extent, in corporate reorganizations involving stubs, spin-offs, and liquidations.